Tracey Regan | Authors


Brentuximab Vedotin as Frontline Therapy in Diffuse Large B-Cell Lymphoma

November 05, 2013

The efficacy and safety of adding the experimental agent brentuximab vedotin (Adcetris) to standard chemotherapy to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is being evaluated in a randomized, open-label phase II trial.